Cyclopharm Ltd
ASX:CYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Veolia Environnement SA
XBER:VVDH
|
FR |
|
M
|
Metsera Inc
NASDAQ:MTSR
|
US |
Cyclopharm Ltd
Research & Development
Cyclopharm Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Research & Development
-AU$614.7k
|
CAGR 3-Years
44%
|
CAGR 5-Years
30%
|
CAGR 10-Years
2%
|
|
|
Somnomed Ltd
ASX:SOM
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Research & Development
-AU$299.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Research & Development
-AU$5.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-15%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Research & Development
-AU$3.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Cyclopharm Ltd
Glance View
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
See Also
What is Cyclopharm Ltd's Research & Development?
Research & Development
-614.7k
AUD
Based on the financial report for Dec 31, 2025, Cyclopharm Ltd's Research & Development amounts to -614.7k AUD.
What is Cyclopharm Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
2%
Over the last year, the Research & Development growth was -68%. The average annual Research & Development growth rates for Cyclopharm Ltd have been 44% over the past three years , 30% over the past five years , and 2% over the past ten years .
